Furthermore, oral treatment with 9-cis -retinyl acetate improved retinal function and vision in LCA patients with mutations in LRAT and RPE658,9, suggesting that precursors of 9-cis retinoids may present a new treatment strategy for patients with mutations in the genes of the retinoid cycle. The gene discussed is LRAT; the disease is Leber congenital amaurosis.